Back
ESC Professional Premium Access

Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study

Session: Coronary artery disease - Pharmacotherapy 3
Topic: Pharmacotherapy
Speaker: Doctor A. Spirito (New York, US)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Alessandro Spirito

Icahn School of Medicine at Mount Sinai, New York (United States of America)
0 follower

6 more presentations in this session

Effect of exercise-based cardiac rehabilitation on the ischemic threshold in patients with high-risk ischemic heart disease

Speaker: Doctor J. Lara Vargas (Ciudad de Mexico, MX)

Access
Abstract
Slides
Like
Thumbnail

Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis of cohort studies

Speaker: Mr S. Soulaidopoulos (Athens, GR)

Access
Abstract
Slides
Like
Thumbnail

Low dose rivaroxaban therapy in aspirin allergic patients undergoing percutaneous coronary intervention

Speaker: Doctor S. Manjooran (London, GB)

Access
Abstract
Slides
Like
Thumbnail

Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial

Speaker: Doctor S. Patel (Boston, US)

Access
Abstract
Slides
Like
Thumbnail

Thrombin generation and endothelial progenitor cell function among patients with acute myocardial infarction treated with prasugrel versus ticagrelor

Speaker: Doctor M. Wiessman (Dallas, US)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Coronary artery disease - Pharmacotherapy 3

Speakers: Doctor A. Spirito, Doctor J. Lara Vargas, Mr S. Soulaidopoulos, Doctor S. Manjooran, Doctor S. Patel...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources